HLB bioStep Co.,Ltd. (KOSDAQ: 278650)

Market Cap	201.49B
Revenue (ttm)	49.17B
Net Income (ttm)	-6.15B
Shares Out	85.56M
EPS (ttm)	-78.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,343
Open	2,355.00
Previous Close	2,355.00
Day's Range	2,355.00 - 2,410.00
52-Week Range	2,155.00 - 4,705.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About HLB bioStep Co.,Ltd.

HLB bioStep Co.,Ltd. provides various test services. It offers platform technology services, such as cell-enzyme-based screening, xenograft assay, mitogenic effect test, vaccine antigen, antibody titration, cytokine, MRNA expression, trachea relaxation assay, carrageenan, adjuvant induced paw edema, antipyretic, anti-pain test, isolated blood vessel screening, fibrin plate lysis screening, ferric chloride induced model, food diet induced model, gastric acid secretion, emesis model, MIC test, post antibody effect, enzyme assay, systemic, local i...

• Industry: Commercial Physical and Biological Research
• Founded: 2012
• Employees: 151
• Stock Exchange: KOSDAQ
• Ticker Symbol: 278650

Financial Performance

In 2023, HLB bioStep Co.,Ltd.'s revenue was 52.81 billion, a decrease of -38.79% compared to the previous year's 86.28 billion. Losses were -164.04 million, -83.73% less than in 2022.